The rationale behind the Myeloma UK Clinical Trial Network

Eric Low, Chief Executive at Myeloma UK,London, UK explains why there was a need for a Clinical Trial Network for multiple myeloma (MM). He talks about the National Institute for Health and Care Excellence (NICE) appraisal of the myeloma drug bortezomib; contrary to expectation at the time, the drug was not approved by NICE. He further discusses the development of the VELCADE Response Scheme and the realization that the drug development system is flawed. They decided to create an academic research consortia that could partner with industry, which would allow for the creation of local real world data and improve the likelihood that NICE would approve a given drug. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.

Share this video